Pulmonary Fibrosis News

June 14, 2022June 14, 2022

AMP945 as Effective as Ofev in IPF Mouse Model; Phase 2 Trial Planned

The experimental oral therapy AMP945, from Amplia Therapeutics, is as effective as the approved therapy Ofev (nintedanib) at reducing tissue scarring, or fibrosis, in a mouse model of idiopathic pulmonary ... Read more

June 10, 2022June 10, 2022

NORD’s ‘Living Rare, Living Stronger’ Patient, Family Forum Set for June 26

COVID-19 News, Pulmonary Fibrosis News

The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in ... Read more

June 7, 2022June 7, 2022

Inconsistent Preclinical Results Delay NXP002’s Potential Move to Trials

Pulmonary Fibrosis News

Inconsistent results in the final planned preclinical study of NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), delayed completion of the preclinical data package needed for a potential ... Read more

June 3, 2022June 3, 2022

New Esbriet Generic PF Treatment Now Available In US

COVID-19 News, Pulmonary Fibrosis News

Accord Healthcare has released a generic version of Esbriet (pirfenidone) for people in the U.S. with idiopathic pulmonary fibrosis (IPF). First approved by the U.S. Food and Drug Administration (FDA) ... Read more

May 31, 2022May 31, 2022

Metformin Use Tied to Reduced Mortality in IPF, Diabetes

Pulmonary Fibrosis News

Treatment with metformin, a medication commonly used to lower blood sugar levels in people with diabetes, was associated with a significantly lower risk of death or hospitalization in patients with ... Read more

May 27, 2022May 27, 2022

TTI-101 Receives FDA’s Orphan Drug Status for IPF

Pulmonary Fibrosis News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Tvardi Therapeutics’ TTI-101 for the treatment of idiopathic pulmonary fibrosis (IPF). TTI-101 is a small molecule, given orally, that ... Read more

May 24, 2022May 24, 2022

With Positive Early Findings, Phase 2 Cudetaxestat Trial Expected Soon

Pulmonary Fibrosis News

Blade Therapeutics’ experimental oral therapy, Cudetaxestat (BLD-0409), was found to significantly reduce lung scarring (fibrosis) and the levels of fibrotic markers and pro-fibrotic molecules in a mouse model of pulmonary ... Read more

May 20, 2022May 20, 2022

BI 1015550 Slows IPF Lung Function Decline in Phase 2 Clinical Trial

COVID-19 News, Pulmonary Fibrosis News

Boehringer Ingelheim’s experimental oral therapy, BI 1015550, slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), regardless of whether they were receiving approved anti-scarring therapies, according to final data ... Read more

May 17, 2022May 17, 2022

Angion Biomedica Cleared for Phase 1B Trial of ANG-3070 in IPF

Pulmonary Fibrosis News

The U.S. Food and Drug Administration (FDA) has given permission for Angion Biomedica to launch a Phase clinical 1b trial to test its experimental anti-fibrotic medication ANG-3070 in people with ... Read more

May 17, 2022May 17, 2022

Generic Version of IPF Therapy Esbriet Now Available in US

Pulmonary Fibrosis News

Sandoz has launched a generic version of Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF) in the U.S. The new generic is available now via specialty pharmacies and there ... Read more

May 13, 2022May 13, 2022

Ofev for PF-ILD Now Reimbursed in 7 regions of Canada

Pulmonary Fibrosis News

Ofev (nintedanib), a medicine approved to treat progressive fibrosing interstitial lung disease (PF-ILD), now is available for public reimbursement in Ontario, Quebec, New Brunswick, Newfoundland and Labrador, Alberta, and the ... Read more

May 10, 2022May 10, 2022

FDA Places PLN-74809, IPF Therapy in Phase 2 Trial, on Fast Track

Pulmonary Fibrosis News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to PLN-74809, now in a Phase 2 clinical trial, as a potential treatment for idiopathic pulmonary fibrosis (IPF). ... Read more

May 6, 2022May 6, 2022

Organizations Rally to Help Ukrainian Rare Disease Patients

Pulmonary Fibrosis News

A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ... Read more

May 3, 2022May 4, 2022

GALACTIC-1 Trial of Inhaled IPF Therapy Hits Enrollment Target

Pulmonary Fibrosis News

Less than 14 months after stopping its GALACTIC-1 study for certain patients due to safety concerns, Galecto has hit its enrollment target for the Phase 2b trial — now under ... Read more

May 3, 2022May 3, 2022

Three Lakes, CHEST Team Up to Shorten Lung Disease Diagnosis Time

Pulmonary Fibrosis News

A new multiphase educational collaboration seeks to slash the time it takes for many people to receive a diagnosis of interstitial lung disease (ILD), including pulmonary fibrosis (PF). The Three ... Read more